Cannabinoid blend helps fight against brain cancer
- Date: 20/04/20
- Author: Daniel Mathers
- Team: Global Vision Biotechnologies - Press Team
Global Vision Biotech’s latest cannabinoid formulation has resulted in improved treatment of the most aggressive brain cancers in on-going, research conducted in collaboration with the National Institute of Biology and University Medical Centre Canada.
The latest blend has doubled the effectiveness of the formulation to induce the death of cancerous glioblastoma multiforme cells, with potentially fewer negative, patient side effects than other blends, according to Dr James Rollins, Head of Cannabinoid Research at Global Vision Biotech.
The company said this latest pre-clinical, in-vitro research enhances the positive work already completed in the middle of last year to test the ability of various cannabinoid compound formulations to inhibit the viability of cancerous glioblastoma cells taken directly from a patient.
The latest results from testing on brain tissue samples from a total of 24 patients have confirmed that cannabinoid preparations can successfully inhibit tumour cell viability and cause a significant percentage of glioblastoma cells to undergo “programmed cell death”, or “apoptosis”, after a short time following application, according to the company.
The current research introduced Cannabigerol, or “CBG”, an additional non-intoxicating cannabinoid as an anti-cancer agent to the formulation containing Cannabidiol, or “CBD”. The latest data shows that adding CBG to CBD doubled the cytotoxic effect on glioblastoma cells.
While CBD inhibits the tumours viability, CBG is more efficient in setting off the cascade of biological processes leading to the apoptosis of glioblastoma cells. Furthermore, the combination of CBG and CBD induced apoptosis without a need for including Tetrahydrocannabinol, or “THC”, thus enabling the development of a therapeutic intervention devoid of psychotropic effects.
Research also shows that the CBG termination effects act specifically on glioblastoma stem cells, which tend to be extremely resistant to irradiation and chemotherapy treatments. Glioblastoma stem cells are considered to be the “roots” of the disease, which is the most aggressive and therapeutically resistant primary brain tumour, making it a key target in oncology therapy, Dr Rollins said.
The Global Vision Biotech research team is now testing the potential for the addition of CBG to avoid the immunological side effects of CBD, while enhancing its desirable impact on the viability of the glioblastoma cells.